Delivery strategies and potential targets for siRNA in major cancer types

So Jin Lee; Min Ju Kim; Ick Chan Kwon; Thomas M. Roberts

doi:10.1016/j.addr.2016.05.010

Delivery strategies and potential targets for siRNA in major cancer types

So Jin Lee, Min Ju Kim, Ick Chan Kwon, Thomas M. Roberts

Research output: Contribution to journal › Review article › peer-review

117 Citations (Scopus)

Abstract

Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.

Original language	English
Pages (from-to)	2-15
Number of pages	14
Journal	Advanced Drug Delivery Reviews
Volume	104
DOIs	https://doi.org/10.1016/j.addr.2016.05.010
Publication status	Published - 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier B.V.

Keywords

Cancer
Delivery strategy of siRNAs
Gene target
Small interfering RNA (siRNA)
siRNA therapeutics

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.addr.2016.05.010

Cite this

@article{c3997924b8634524bdfb1c3c01dcfee9,

title = "Delivery strategies and potential targets for siRNA in major cancer types",

abstract = "Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.",

keywords = "Cancer, Delivery strategy of siRNAs, Gene target, Small interfering RNA (siRNA), siRNA therapeutics",

author = "Lee, {So Jin} and Kim, {Min Ju} and Kwon, {Ick Chan} and Roberts, {Thomas M.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier B.V.",

year = "2016",

doi = "10.1016/j.addr.2016.05.010",

language = "English",

volume = "104",

pages = "2--15",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Delivery strategies and potential targets for siRNA in major cancer types

AU - Lee, So Jin

AU - Kim, Min Ju

AU - Kwon, Ick Chan

AU - Roberts, Thomas M.

PY - 2016

Y1 - 2016

N2 - Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.

AB - Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.

KW - Cancer

KW - Delivery strategy of siRNAs

KW - Gene target

KW - Small interfering RNA (siRNA)

KW - siRNA therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84973527084&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2016.05.010

DO - 10.1016/j.addr.2016.05.010

M3 - Review article

C2 - 27259398

AN - SCOPUS:84973527084

SN - 0169-409X

VL - 104

SP - 2

EP - 15

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

Delivery strategies and potential targets for siRNA in major cancer types

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this